Canada Pension Plan Investment Board Acquires 11,568 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Canada Pension Plan Investment Board raised its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 6.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 199,170 shares of the medical device company’s stock after buying an additional 11,568 shares during the period. Canada Pension Plan Investment Board owned about 0.10% of Cooper Companies worth $18,310,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Byrne Asset Management LLC bought a new position in Cooper Companies in the 4th quarter valued at about $33,000. OFI Invest Asset Management bought a new position in shares of Cooper Companies during the fourth quarter worth approximately $34,000. New Age Alpha Advisors LLC acquired a new stake in Cooper Companies during the 4th quarter worth approximately $38,000. Covestor Ltd lifted its holdings in Cooper Companies by 35.5% during the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after purchasing an additional 120 shares during the last quarter. Finally, West Financial Advisors LLC bought a new stake in Cooper Companies in the 4th quarter valued at $49,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Price Performance

Cooper Companies stock opened at $79.51 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The Cooper Companies, Inc. has a 52 week low of $69.81 and a 52 week high of $112.38. The stock has a market capitalization of $15.90 billion, a P/E ratio of 40.77, a price-to-earnings-growth ratio of 2.25 and a beta of 1.01. The stock has a fifty day moving average of $83.06 and a 200-day moving average of $93.48.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. On average, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COO has been the subject of a number of research reports. Robert W. Baird dropped their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Stifel Nicolaus cut their price objective on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday, March 7th. JPMorgan Chase & Co. lowered their target price on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Citigroup cut their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Finally, Piper Sandler restated an “overweight” rating and set a $115.00 price objective (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.